PubMed HealthSearch

Biomedical subjects

Z Szekanecz

Publications and source records attributed to Z Szekanecz.

4 recordsLinked to original sources

[Cell surface adhesion molecules: structure, function, clinical aspects].

Intercellular and cell-matrix interactions play a crucial role in several physiological and pathological processes. These relationships are based on different cell adhesion molecules. Although adhesion receptors exhibit structural diversity, cell adhesion mechanisms are basically similar to each other. Details of receptor functions (e.g. the exact mechanisms of signal transduction) is poorly understood. In this paper authors summarize data on different cell adhesion antigens and also describe a few important biological features to collect more data on the complex interactions of these molecules.

Cell Adhesion Molecules

Lymphocyte adhesion to high endothelium is mediated by two beta 1 integrin receptors for fibronectin, alpha 4 beta 1 and alpha 5 beta 1.

Using a rat model we have previously proposed a role for fibronectin as an adhesive ligand on high endothelial cells (HEC) for recirculating lymphocytes. Lymphocyte adhesion to high endothelial cells was blocked by CS1 peptide (from the type III connecting segment of fibronectin) and RGD-containing peptides using two different in vitro assays of lymphocyte-HEC recognition, the frozen section assay and cultured HEC. In order to study the receptors utilised by lymphocytes to bind to HEC we have developed a xenogeneic model in which the adhesion of human lymphocytes to HEC cultured from rat lymph nodes is measured. The basic properties of lymphocyte-HEC interaction were retained using human lymphocytes. CS1 peptide and RGD-containing peptides gave similar profiles of inhibition of lymphocyte adhesion as found previously using rat cells. FACS analysis showed that the majority of peripheral blood lymphocytes expressed two beta 1 integrin receptors, alpha 4 beta 1 and alpha 5 beta 1, which are known to recognise distinct adhesion domains in fibronectin. A subpopulation of lymphocytes also expressed alpha 3 beta 1, which, like alpha 5 beta 1, has been reported to be an RGD-dependent adhesion receptor for the central cell binding domain of fibronectin. Anti-alpha 4 and anti-alpha 5 subunit monoclonal antibodies maximally inhibited adhesion to HEC by 60% and 65%, respectively. Monoclonal antibodies to the common beta 1 subunit gave slightly higher inhibition at 70%. These results suggest that lymphocytes employ one or both of two different beta 1 integrin fibronectin receptors to bind to HEC. The simultaneous or alternate engagement of two fibronectin receptors on the lymphocyte surface by immobilised fibronectin in the endothelial layer may contribute to the stabilisation of adhesive contacts or to the subsequent transendothelial migration of lymphocytes. In contrast to lymphocytes, peripheral blood neutrophils did not express any members of the beta 1 integrin family. The selective expression of beta 1 integrins by lymphocytes and not neutrophils contrasted with the widespread distribution of the other homing-associated adhesion molecules, LECAM-1, CD44 and LFA-1, on these two cell types. It is thus possible that the selective expression of beta 1 integrins regulates the constitutive migration of lymphocytes but not neutrophils into organised lymphoid tissues.

Amino Acid Sequence

Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis.

BACKGROUND: Cross-reactivity between anti-DNA antibodies and heparan sulfate (HS)/heparan sulfate-proteoglycan (HS-PG) of glomerular basement membrane has been previously reported. Conceivably, this determines the final outcome of glomerular injury in lupus nephritis. EXPERIMENTAL DESIGN: We investigated the status of glomerular injury in NZB/NZW F1 mice after the administration of rabbit anti-HS-PG antibody (experiment group). The controls received normal rabbit IgG only. RESULTS: All experimental animals became proteinuric 2 weeks after the administration of anti-HS-PG. The animals of the older age group (16 weeks) had significant hematuria as well. Their glomeruli exhibited hypercellularity with a heavy influx of polymorphonuclear leukocytes and monocytes into their capillaries, and some of them exhibited crescentic changes. Electron-dense deposits were present in subepithelial, subendothelial, and mesangial regions of the glomeruli. The control group had normocellular glomeruli with a few mesangial deposits. Mouse IgG and C3 displayed a granular pattern of immunofluorescence in the experimental group. Anti-rabbit IgG titers in the serum were higher in the control group, which lower in the renal glomerular eluates. No significant differences were observed in the concentrations of anti-dsDNA and -ssDNA either in the sera or in the eluates. There was also no difference between the control and experimental group in terms of antibody synthesis by the splenic lymphocytes and their proliferation subsequent to antigenic challenge. CONCLUSIONS: Data suggest that administration of anti-HS-PG accentuates the glomerular injury during the natural course of lupus nephritis in (NZB/NZW F1 mice; seemingly these two antibodies (anti-HS-PG and -DNA) do not competitively inhibit the binding of the other to the same anionic sites of glomerular basement membrane enriched with heparan sulfate in vivo.

Animals

Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases.

Impaired mononuclear leucocyte (MNL) motility can be found both in vascular and autoimmune diseases. Pentoxifylline (PTX) has a well-known therapeutic effect in vascular diseases, which is based on the rearrangement of blood cell cytoskeleton and thus increased microcirculatory flow. Most data on PTX concern red blood cells and granulocytes so now the effect of PTX on previously decreased MNL migration and chemotaxis was investigated in vitro. The results of MNL chemotaxis studies described here suggest that this drug enhances impaired MNL motility in obliterative atherosclerosis and systemic lupus erythematosus and thus may also be introduced in the treatment of certain polysystemic autoimmune diseases with decreased in vitro MNL chemotaxis.

Adult